New Phase 2 Trial to Test NYX-2925 as Potential Fibromyalgia Therapy
News
A new Phase 2 clinical trial will continue to assess the safety and effectiveness of the non-opioid small molecule candidate therapy NYX-2925, developed by Aptinyx, in fibromyalgia patients. NYX-2925 is an oral ... Read more